# Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

> **NCT06001151** · PHASE2 · RECRUITING · sponsor: **Qian Chu** · enrollment: 49 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Cadonilimab
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06001151
- **Lead sponsor:** Qian Chu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-07
- **Primary completion:** 2025-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2023-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06001151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06001151, "Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06001151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*